Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 7, 2015; 21(37): 10654-10661
Published online Oct 7, 2015. doi: 10.3748/wjg.v21.i37.10654
Published online Oct 7, 2015. doi: 10.3748/wjg.v21.i37.10654
Histological healing after infliximab induction therapy in children with ulcerative colitis
Anna Wiernicka, Maciej Dadalski, Jaroslaw Kierkus, Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children’s Memorial Health Institute, 04-730 Warsaw, Poland
Sylwia Szymanska, Joanna Cielecka-Kuszyk, Department of Pathology, The Children’s Memorial Health Institute, 04-730 Warsaw, Poland
Author contributions: Wiernicka A collected and analyzed the data, and wrote the manuscript; Kierkus J designed and supervised the study and revised the manuscript; Dadalski M supervised statistical analysis, collected the clinical data, and revised the manuscript; Szymanska S and Cielecka-Kuszyk J collected and analyzed biopsy specimens; all the authors have read and approved the final version to be published.
Supported by The Children’s Memorial Health Institute Internal Grant S129/2013 (in part).
Institutional review board statement: The study was reviewed and approved by the local Ethics Committee of the Children’s Memorial Health Institute, Warsaw, Poland (nr 179/KBE/2014).
Conflict-of-interest statement: The authors declare that there are no conflicts of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Jaroslaw Kierkus, Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children’s Memorial Health Institute, Al. Dzieci Polskich 20, 04-730 Warsaw, Poland. j.kierkus@czd.pl
Telephone: +48-22-8157392 Fax: +48-22-8157392
Received: March 7, 2015
Peer-review started: March 11, 2015
First decision: April 20, 2015
Revised: May 14, 2015
Accepted: June 16, 2015
Article in press: June 16, 2015
Published online: October 7, 2015
Peer-review started: March 11, 2015
First decision: April 20, 2015
Revised: May 14, 2015
Accepted: June 16, 2015
Article in press: June 16, 2015
Published online: October 7, 2015
Core Tip
Core tip: The impact of infliximab induction therapy on histological healing in pediatric ulcerative colitis (UC) patients is unknown. The present study demonstrates that infliximab induction therapy had a positive influence on histological changes expressed by normal surface, crypt architecture, number of crypts, and lamina propria cellularity in 37.5% of UC patients. The treatment was effective in reducing intestinal inflammation as assessed by the Geboes Index (62.5% of patients). Furthermore, it was shown that there was no significant correlation of histological healing with endoscopic remission and clinical remission.